|
|
|
|
Search published articles |
|
|
Showing 2 results for Iranijam
Farnaz Ehdaivand, Masoumeh Rostamnejad , Effat Iranijam , Volume 4, Issue 4 (Winter 2004)
Abstract
Background & Objectives: Hypertension is the most common medical problem in pregnancy, with an incidence rate of 6-8%. The patients with preeclampsia are exposed to more maternal and fetal complications. This requires more intensive prenatal cares. The diagnosis in early stages of disease has an important role in decreasing maternal and neonatal mortality and its comsequent complications. This study was an attempt to determine the epidemiological factors and complications of preeclampsia among patients admitted to Alavi hospital, Ardabil. Methods: This descriptive retrospective study was conducted on 176 women with preeclampsia. The data were collected using a questionnaire and medical records of patients. These data were analyzed using descriptive and inferential statistics. Results: 75% of the patients had severe preeclampsia and 25% had mild preedampsia. Regarding the predisposing factors, history of preeclampsia was observed in 23.1% of the cases, mother's underlying diseases in 12.5%, twin in 2.3% and hydramnios in 4%. The method of delivery in 62.5% of the cases was cesarean section. 67.6% of preeclamptic patients had maternal and fetal complications (10.2% Maternal and 57.4% fetal). The maternal complications were: abruptio placenta, (44.4%), eclampsia (22.2%) and coma (11.1%). The fetal complications were: IUGR (42.4%), prematurity (39.6%) and IUFD (9%). Conclusion: In this study the incidence of severe preeclampsia was higher, which may be due to insufficient prenatal cares and delay in diagnosis. Further studies about the effect of prenatal cares on pregnancy outcomes in preeclamtic women are recommended.
Effat Iranijam, Mohammad Hossein Hosseini, Mohammad Negaresh, Elham Yousefi Ardabili, Volume 22, Issue 4 (Winter 2023)
Abstract
A severe acute respiratory syndrome caused by coronavirus 2 infection (COVID-19)was identified in December 2019 and caused a massive pandemic that claimed millions of lives worldwide. The Chimpanzee adenovirus vector vaccine is one of the few vaccines against coronavirus disease in 2020. This case report introduces, a patient who developed thrombocytopenia, fever, and lethargy nine days after vaccination with the chimpanzee adenovirus carrier vaccine. The patient was admitted to the hospital and thrombotic thrombocytopenic purpura (TTP) symptoms appeared during hospitalization.
|
|
|
|
|
|